Ozempic on the OR Table: The New Pre-Surgery Fasting Playbook for GLP-1 Users

The concern is mechanical, not mysterious. GLP-1 receptor agonists — semaglutide, tirzepatide and their cousins — slow gastric emptying. That is part of why they work for appetite and glycemic control. It is also why anesthesiologists worry about residual gastric content (RGC): food or fluid still sitting in the stomach when you go under, which in theory can be regurgitated and aspirated into the lungs. A 2026 systematic review in Cureus pulled together nineteen clinical studies plus one large claims dataset to ask a sharper question: what actually reduces that residual content, and does it line up with the real, much rarer event of aspiration?

The headline finding for a busy 40-year-old is that fasting protocol may matter more than the heroic week-long drug hold everyone has been arguing about. In one retrospective study cited in the review, patients on a 24-hour clear-liquid diet before their procedure had high residual gastric content roughly one to two percent of the time, versus about ten percent on standard fasting — an odds ratio near 0.13. That is a large effect for a behavioral change you can actually execute the day before surgery.

Society guidance over the last two years has swung between aggressive medication holds and a more measured "individualize it" stance. The Cureus synthesis lands somewhere pragmatic. In prospective ultrasound studies, withholding weekly GLP-1 RAs for seven to eight days before a procedure was associated with lower odds of high residual gastric content compared with shorter intervals. That is consistent with the long half-lives of these drugs and the time it takes gastric motility to normalize.

But — and this is the part the headlines keep missing — residual gastric content is a surrogate. It is what shows up on the ultrasound screen, not what shows up in the recovery room. Clinical aspiration is rare. The review is explicit that RGC and aspiration are distinct outcomes, and the evidence base does not yet prove that aggressive drug holds translate into fewer real aspiration events. For a healthy adult getting an elective procedure, that distinction matters: pausing your weekly injection has its own costs — rebound appetite, glycemic swings, missed momentum — and those costs only buy you something if the marginal aspiration risk is actually moving.

The most interesting through-line in the review is the rise of gastric point-of-care ultrasound, or POCUS. Multiple studies used validated thresholds — broadly, an antral content estimate above roughly 1.5 mL/kg, or the presence of solid material — to decide, at the bedside, whether a given GLP-1 user actually has a full stomach right now. Instead of treating every semaglutide patient as a default aspiration risk and cancelling cases or delaying them by a week, the team scans, looks, and decides.

That is a meaningfully different posture. It moves the decision from a population-level rule ("hold the drug for everyone") to an individual-level measurement ("this stomach, today, is empty enough"). It also gives the anesthesiologist a clean Plan B: if the antrum looks loaded, you can postpone, switch to a rapid-sequence induction, or extend clear-liquid fasting and rescan. The catch is access. POCUS requires a clinician trained in the gastric protocol and a machine in the pre-op bay. Big academic centers increasingly have both. Your local ambulatory surgery center may not.

You are not the one writing the pre-op order. But you are the one who tells the surgical team you are on a GLP-1 — and that disclosure shapes everything downstream. The practical move, weeks before any elective procedure, is to flag the medication early, ask whether the facility uses gastric POCUS, and ask what fasting protocol they want from you. The review suggests an extended clear-liquid window the day before is a high-leverage, low-cost intervention. A longer drug hold is a separate decision that should weigh your metabolic situation, not just a default policy.

The honest read on the evidence is moderate, not definitive. Nineteen heterogeneous studies, no meta-analysis, surrogate outcomes, and a still-thin link between RGC and clinical aspiration mean the field is converging, not settled. Expect society guidelines to keep moving. What looks durable is the direction of travel: away from blunt week-long holds, toward smarter fasting plus a quick look with an ultrasound probe.